Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine Infusions in Major Depressive Disorder
NCT03065335Phase 1Recruiting
- Sponsor
- National Institute of Mental Health
- Start
- May 2017
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ketamine in major depressive disorder (MDD) (4 arms), sponsored by National Institute of Mental Health. Primary endpoints: Neuropharmacodynamic effects measured by fMRI+EEG and MEG, Ketamine metabolites crossing the blood brain barrier and 1 more. Started May 2017; status: recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03065335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03065335.